MedTrace Logo

Trial of JYB1904 in Patients With Allergic Asthma

NCT06438757 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2025-05-07

No results posted yet for this study

Summary

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Conditions

  • Allergic Asthma

Interventions

DRUG

JYB1904

Participants will receive JYB1904 every 8 weeks for 24 weeks.

DRUG

Omalizumab

Participants will receive Omalizumab every 2/4 weeks for 24 weeks.

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Min Zhang · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06438757 on ClinicalTrials.gov